

# **505 Q4**

QUARTERLY UPDATE
ASX.CD3





# QUARTERLY INVESTMENT UPDATE FUND 3 (ASX: CD3)

In 2024, U.S. private equity (PE) saw a strong rebound in activity which was a welcome change from the prior 12-month period. Deal count and deal value both saw significant year-over-year increases, driven by lower interest rates which help in aligning buyer and seller valuation expectations as well as allowing deals to proceed with confidence. Exit activity was also helped along by secondary buyouts, with PE firms acquiring 79 companies from other PE firms, with an aggregate value of US\$167b, which was up by over 100% from the year prior.


Despite a modest slowdown in Q4 2024 due to the U.S. Presidential Election, momentum was also fuelled by increasing pressure for capital returns from limited partners (LPs). EY surveyed US General Partners (GPs), with 57% expecting exits to increase over the next six months and for many, their exit readiness activities – inclusive of presale diligence, engaging bankers to help manage the sale, and preparing management teams for the process – has already begun in earnest. We are noticing this amongst the Fund Series – particularly CD1 and CD2 – and are hopeful for a fruitful 2025 for these portfolios.

Overall, the macroeconomic backdrop does remain mixed, despite a largely pro-business Government, risks such as tariffs, persistent high interest rates, budget cuts, and inflationary pressures from supply chain disruptions and consumer defaults all pose different pressures on the portfolio companies. While caution may persist, we are hopeful that our GPs can position themselves to benefit from an improving business climate in 2025 and capitalise on the increased market activity for their LPs.

# FUND 3: QUARTERLY UPDATE & PORTFOLIO COMPOSITION1.5,6,7

| Inception Date  | July 2016        |  |  |
|---|------------------|--|--|
| CD3 Original Unit Price   | \$1.60 per unit  |  |  |
| CD3 Distributions Paid Since Inception <sup>8</sup>                     | \$1.909 per unit |  |  |
| CD3 31 December 2024 NTA (post-tax)                                     | \$1.95 per unit  |  |  |
| Q4 2024 Portfolio Realisations<br>Average Gross MOIC on Q4 Realisations | 7<br>2.43x       |  |  |
| CD3 Interest in LP3   | 71.22%           |  |  |
| Total Underlying Funds (since inception)                                | 13               |  |  |
| Total Underlying Portfolio Companies (since inception)                  | 144              |  |  |
| Total Portfolio Company Realisations                                    | 74               |  |  |
| Median Gross MOIC on Realisations                                       | 2.8x             |  |  |
| Remaining Portfolio Companies (see below)                               | 64               |  |  |
| Hold Period of Remaining Active Investments                             | 5.4 years        |  |  |
| Fund Cash Balance <sup>9</sup>  | A\$9.5m          |  |  |
| Fund's Interest in LP Cash Balance <sup>9</sup>                         | US\$11.7m        |  |  |
| Fund's Interest in Underlying Funds                                     | US\$53.5m        |  |  |
| Fund's Interest in US Select Direct 2 (USD2)                            | US\$26.7         |  |  |

| CD3 31 DECEMBER 2024: KEY STATISTICS <sup>1, 2</sup> |                  |                         |  |  |
|--|------------------|-------------------------|--|--|
| NTA per unit   | Gross assets     | Quarterly<br>NTA Return |  |  |
| \$1.95   | A\$147.5 million | 14.0%                   |  |  |



As at 31 December 2024, the Fund had 70 portfolio companies, with six (6) of those deemed <u>inactive</u> and unlikely to have significant value extracted.

Of the remaining 64 portfolio companies, it is considered that 50 of these are <u>active earners</u>, and 14 have been <u>impaired</u> from their cost base in prior periods. Though these 14 have been impaired, they do still continue to hold value and a number have already returned capital during the hold period.

# **CASH FLOW MANAGEMENT (FUND 3 & LP3)**

In light of the recent distributions announced in January 2025 (CD3 announcement of \$0.13 per Unit <a href="here">here</a>), as well as the notable increase in underlying portfolio activity, we've received queries from Investors regarding the underlying cash flow management policies of the Fund, which we are pleased to share more detail on. The below is a snapshot of the Fund and LP cash following the distribution announced to Unitholders, which was partially funded by a distribution from the LP to the Fund.

Similar principles to what K2 shared in the October 2023 presentation apply (presentation here), with distributions being determined based on available and projected cash flows at both the Fund level (managed by K2 as the RE) and at the LP level (managed by the General Partner (GP)). The RE does not have discretion over the cash management of the LP.

|                                       | as at 7 February 2025 |
|---------------------------------------|-----------------------|
| CD3 (Fund 3) Cash (AUD)               | A\$19.5m              |
| ALLOWANCE FOR                         |                       |
| Distributions declared (January 2025) | -A\$9.4m              |
| Further investments                   | -A\$5.0m              |
| Working capital & fund expenses*      | -A\$4.3m              |
| Total Cash Requirement                | -A\$18.7m             |
|                                       |                       |
| Cash Buffer^                          | A\$0.8m               |

\*Working capital includes a projected 3 year period of management & administration fees, professional fees, ASX fees (where applicable), registry fees, accounting, audit & compliance, as well as an allowance for any expected Fund-level taxes.

^While we work to keep this cash buffer as modest as possible, conservatively we wish to be able to account for any unforeseen Fund level expenses or unfavourable FX movements.

|  | as at 7 February 2025 |
|--|-----------------------|
| LP3 Cash (USD)   | US\$7.4m              |
| LP3's Remaining Commitment to Underlying Funds <sup>1, 8</sup> | -US\$5.6m             |
| LP3 2025 Investment<br>Manager Fees <sup>10</sup>              | -US\$1.1m             |
|  |                       |
| Fund's Interest in LP3   | 71.22%                |
| Fund's non-controlling interest in LP3 Cash                    | US\$5.3m              |

The LP's remaining capital commitments are subject to change as allowed under the individual Limited Partnership Agreement (LPA). Though the remaining commitment will change with each capital call or distribution, it is the Manager's expectation that the underlying Funds will not call this full amount, and that any capital calls should be funded by distributions in the future.

### LP3 QUARTERLY CAPITAL CALLS & DISTRIBUTIONS1

|              | MONTH    | AMOUNT*    | FUND                       | PRIMARY REASON   |
|--------------|----------|------------|----------------------------|--|
| Distribution | October  | US\$0.14m  | Encore Consumer<br>Capital | Escrow & tax release: Murry's, Supergoop! & 4505 Meats |
| Capital Call | November | -US\$0.08m | DFW Capital Partners       | Follow on investment: Continuum Research<br>Group      |
| Distribution | November | US\$1.77m  | Growth Street Partners     | Realisation: Visual Lease                              |
| Distribution | November | US\$3.43m  | Gemspring Capital          | Realisation: Shrieve Acquisition Corp                  |
| Capital Call | December | -US\$0.01m | DFW Capital Partners       | Management fees & partnership expenses                 |
| Distribution | December | US\$0.02m  | Incline Equity Partners    | Escrow release: ARMStrong LLC                          |
| Distribution | December | US\$1.79m  | NMS Fund III               | Realisation: Center for Social Dynamics                |
| Distribution | December | US\$1.64m  | Incline Equity Partners    | Realisation: Unified Power                             |

Note: This table does not account for all cash flow movements of the LP during the month.

\*Amount of distributions may include simultaneous capital calls for minor follow-on investments, tax withholdings or payments, management fees & partnership expenses and/or carried interest payments.

## LP3 QUARTERLY PORTFOLIO REALISATIONS - CASH EVENTS<sup>1</sup>









After a hold period of 6 years, the company was acquired by CoStar Group (NASDAQ: CSGP) and in their third-auarter conference call, executives at CoStar said it made the acquisition for US\$272.5 million.

Shrieve was first acquired by Gemspring in 2019 and through Gemspring's operational and financial resources, they were able to enter new markets, add key personnel, bolster capabilities, and significantly enhanced product offerings for customers while maintaining exceptional service.

Incline first invested in the company in 2019, and during the hold period they were able to complete seven addon acquisitions, broadening the geographic footprint, as well as improving efficiency, productivity and customer satisfaction.

CSD is a leading provider of applied behaviour analysis ("ABA") to children with Autism Spectrum Disorder ("ASD"). NMS first invested in the company in 2019 and during the hold period they were able to accelerate growth in new and existing geographies as well as implement a strong leadership team for the business.

Status Realised (2024) **Initial Investment Date** 2018 **Underlying Fund Growth Street Partners**  Status Realised (2024) **Initial Investment Date** 2019 **Underlying Fund** Gemspring

Status Realised (2024) **Initial Investment Date** 2019 **Underlying Fund Incline Equity Partners** 

Status Realised (2024) **Initial Investment Date** 2019 **Underlying Fund** NMS Capital

# LP3 QUARTERLY PORTFOLIO REALISATIONS - NON-CASH EVENTS<sup>1</sup>

# allbirds





Status IPO (2021)

Final parcel sold on market (Dec 2024) **Initial Investment Date** 2017

**Underlying Fund Elephant Partners**  Status

Realised (Dec 2024) Initial Investment Date 2019

**Underlying Fund** Gemspring Capital

Status

Realised (Dec 2024) **Initial Investment Date** 2019

**Underlying Fund** Gemspring Capital

# LP3 UNDERLYING PORTFOLIO1,5,6,7

|         | TOTAL<br>COMPANIES | TOTAL<br>REALISATIONS | MEDIAN<br>MOIC<br>(REALISATIONS) | ACTIVE<br>PORTFOLIO<br>COMPANIES | AVERAGE HOLD<br>PERIOD<br>ON ACTIVE<br>COMPANIES | UNDERLYING<br>FUND VALUE<br>(\$USD millions) | QUARTERLY<br>MOVEMENT<br>(EXCLUDING<br>REALISATIONS)<br>(\$USD millions) |
|---------|--------------------|-----------------------|----------------------------------|----------------------------------|--|--|--|
| Fund 1  | 9                  | 6                     | 4.1x                             | 2                                | 6.2 years  | \$4.46                                       | -\$0.06  |
| Fund 2  | 7                  | 3                     | 2.5x                             | 4                                | 6.7 years  | \$3.83                                       | +\$0.30  |
| Fund 3  | 11                 | 9                     | 3.0x                             | 2                                | 6.7 years  | \$7.62                                       | -\$0.01  |
| Fund 4  | 12                 | 5                     | 2.9x                             | 6                                | 6.2 years  | \$8.77                                       | +\$0.12  |
| Fund 5  | 12                 | 9                     | 3.8x                             | 3                                | 6.6 years  | \$2.97                                       | -\$0.78  |
| Fund 6  | 9                  | 6                     | 7.0x                             | 3                                | 4.0 years  | \$4.05                                       | +\$0.73  |
| Fund 7  | 10                 | 5                     | 3.1x                             | 3                                | 4.9 years  | \$3.39                                       | +\$0.50  |
| Fund 8  | 7                  | 7                     | 2.2x                             | 0                                | -  | \$4.37                                       | -\$0.79  |
| Fund 9  | 8                  | 1                     | 2.1x                             | 7                                | 5.4 years  | \$9.45                                       | -\$0.70  |
| Fund 10 | 12                 | 5                     | 2.3x                             | 7                                | 7.0 years  | \$5.87                                       | +\$0.12  |
| Fund 11 | 7                  | 2                     | 4.3x                             | 5                                | 5.0 years  | \$14.24                                      | +\$3.34  |
| Fund 12 | 15                 | 11                    | 1.2x                             | 4                                | 5.4 years  | \$5.48                                       | -\$0.14  |
| Fund 13 | 25                 | 5                     | 2.0x                             | 18                               | 4.3 years  | \$37.51                                      | +\$2.12  |
| Total   | 144                | 74                    | 2.8x                             | 64                               | 5.4 years  | \$112.03                                     | +\$4.76  |


<sup>\*</sup>Remaining value is at the LP level. Fund 8 has had all underlying portfolio companies substantially exited, with two realisations having approximately 1/3 of the exit proceeds retained as rollover equity. The value not included in the above table, which includes LP cash & Smartsheet as at 31 December 2024, is US\$17.1 million.

# CD3 PERFORMANCE SUMMARY 1, 2, 3, 4

|            | 1 MONTH | 6 MONTHS | 12 MONTHS | 3 YEARS    | 5 YEARS    | SINCE INCEPTION | IRR        |
|------------|---------|----------|-----------|------------|------------|-----------------|------------|
| NTA RETURN | 4.8%    | 12.7%    | 17.6%     | 14.5% p.a. | 20.7% p.a. | 14.4% p.a.      | 13.7% p.a. |

The Fund's NTA return is net of fees (including initial issuer or product fees) and is inclusive of distributions paid. Movement from 30 September 2024 is largely attributable to the weakening of the Australian dollar in combination with positive portfolio valuation movements, as can be seen in the NTA quarterly waterfall graph below.

Historical performance is not a guarantee of the future performance of the Fund.



# CD3 DISTRIBUTION HISTORY (PER UNIT)1,2

|      | Distributions<br>Declared | Cumulative<br>Distributions | NTA<br>as of 31 December | DPI   | TVPI  |
|------|---------------------------|-----------------------------|--------------------------|-------|-------|
| 2018 | \$0.013                   | \$0.013                     | \$1.66                   | 0.01x | 1.05x |
| 2019 | \$0.00                    | \$0.013                     | \$1.86                   | 0.01x | 1.17x |
| 2020 | \$0.00                    | \$0.013                     | \$1.88                   | 0.01x | 1.18x |
| 2021 | \$0.895                   | \$0.908                     | \$2.09                   | 0.57x | 1.87x |
| 2022 | \$0.451                   | \$1.359                     | \$2.17                   | 0.85x | 2.21x |
| 2023 | \$0.33                    | \$1.689                     | \$1.87                   | 1.06x | 2.22x |
| 2024 | \$0.22                    | \$1.909                     | \$1.95                   | 1.26x | 2.41x |
| 2025 | \$0.13                    | \$2.039                     | -                        | 1.27x | -     |

# **GLOSSARY AND NOTES**

Source: E&P Investments Limited (for data before 24 June 2023) and K2 Asset Management Ltd (for data after 24 June 2023).

All figures are in AUD unless otherwise noted. Figures throughout the document may not sum due to rounding. AUD:USD 31 December 2024 spot rate of 0.6188 used. The Unit price of CD3 was \$1.27 as at 31 December 2024, the last trading day of the quarter.

- Data is unaudited and is as at 31 December 2024. 1.
- NTA and total returns are inclusive of distributions and are based on post 2. tax NTA, net of fees and costs.
- Inception date of CD3 was July 2016.
- 4. CD3 original Unitholder investment was \$1.60 per Unit.
- MOIC returns are as at 31 December 2024 and represent all underlying portfolio company sales since inception. MOIC returns are net of all underlying fees and expenses of the individual fund managers, but before fees and expenses of the LP and the Australian Unit Trust. MOIC returns are based on US dollar denominated investments and include US Select Direct II (USD2).
- Age of portfolio companies refers to the average duration of time that the LP has been invested in the remaining underlying portfolio companies. 6.
- LP investments values are based on 30 September 2024 valuations provided by the underlying GP's, adjusted for capital calls, distributions and foreign exchange movements over the period. It is expected that the 31 December 2024 reports, which are based on the underlying Fund's audited financial statements, will be received in April 2025.
- The Manager has confirmed that USD2's remaining callable capital has been excluded from this figure, as the Fund is well capitalised and any future expenses are anticipated to be covered by distributions. R
- These figures are as at 31 December 2024 therefore do not include payment of the distribution declared in January 2025. 9.
- Investment Manager Fee is explained in greater detail in Note 8 of the 2025 Half-Year Accounts (here).

# **DEFINED TERMS**

Portfolio Company: MOIC:

A company that is an investment of the LP. Multiple on Invested Capital. MOIC is calculated by dividing the fund's cumulative distributions and residual

IRR:

value by the paid-in capital.

Internal Rate of Return.

Performance of the fund(s) by taking into account the size and timing of its cash flows (capital calls and distributions) and the Fund's net asset value at the time of the calculation.

Pictribution to Paid-in Capital

DPI:

Distribution to Paid-in Capital (total distributions divided by original investment).

Total Value to Paid-in Capital. (total distributions + current NTA divided by original TVPI:

M&A:

investment). Mergers & Acquistions.

Transactions in which the ownership of companies or their operating units — including all associated assets and liabilities — is transferred to another entity. The year in which a private equity fund makes its first

VINTAGE: investment in the portfolio company.

### **INVESTMENT OBJECTIVES**

The CD Private Equity Fund Series, including CD Private Equity Fund I (ASX: CD1), CD Private Equity Fund II (ASX: CD2), CD Private Equity Fund II (ASX: CD3), and CD Private Equity Fund IV (CD4) (together, Funds or Fund Series), is a series of private equity funds focused on US small-cap private equity funds and direct company investments. The Fund Series investments are selected by a joint venture between the private investment arm of the Cordish Companies of Baltimore, Maryland, and E&P Funds with underlying investments managed by experienced private equity fund managers.

The General Partner and Investment Manager will seek to meet each Fund's aim of providing Unitholders with exposure to a portfolio of investments in small and mid-market private investment funds and privately held companies predominantly focused in the US; and capital growth over the medium to long

### CORDISH EQUITY PARTNERS TEAM



Jonathan Cordish President Cordish Equity Partners



**Jonathan Sinex Managing Director Cordish Equity Partners** 

### RESPONSIBLE ENTITY



K2 Asset Management Ltd (K2) is the Responsible Entity of the Funds. K2 is a listed Australian diversified financial services firm with three core pillars:

- **Funds Management:**
- Responsible Entity (RE) and Trustee Services; and
- Exchange Traded Funds (ETFs).

Established in 1999, K2 is the main operating subsidiary of K2 Asset Management Holdings Ltd which is listed on the Australian Securities Exchange (ASX Code: KAM).

### HISTORICAL PERFORMANCE IS NOT A GUARANTEE OF THE FUTURE PERFORMANCE OF THE FUNDS.

# DISCLOSURES

This Quarterly Update (Update) has been prepared and authorised for release by K2 Asset Management Ltd (K2) as Responsible Entity (ACN 085 445 094, AFSL 244 393) of the CD Private Equity Fund Series (Funds or Fund Series) which includes CD Private Equity Fund I (ARSN 158 625 284) (CD1), CD Private Equity Fund II (ARSN 612 132 813) (CD3), and CD Private Equity Fund IV (ARSN 624 474 531) (CD4). K2 and the Manager have taken reasonable care to ensure that the information contained in this document is accurate at the date of publication. However, no warranty or guarantee (express or implied) is given by either party as to the accuracy of the information in this document, and to the extent permitted by applicable law, K2 and the Manager specifically disclaim any liability for errors, inaccuracies or omissions in this document and for any loss or damage resulting from its use.

The general partner of each of the Limited Partnerships (LPs) in the series has engaged either E&P Funds Management Pty Limited (ACN 159 902 708)(LPI)("E&PFM") or the Investment Manager (LPs II,III,IV) to act as investment manager and/ or investment advisor for each respective underlying LP. An investment in any of the Funds is subject to various risks, many of which are beyond the control of the Investment Manager and the Funds. The past performance of the Funds is not a guarantee of the is subject to various risks, many or which are beyond the control of the investment Manager and the Funds. The past performance of the Funds is not a guarantee of the future performance of the Funds. This Update may contain statements, opinions, projections, forecasts and other material (forward looking statements), based on various assumptions. Those assumptions may or may not prove to be correct. The Responsible Entity and its advisers (including all of their respective directors, consultants and/or employees, related bodies corporate and the directors, shareholders, managers, employees or agents of them) (Parties) do not make any representation as to the accuracy or likelihood of fulfilment of the forward-looking statements or any of the assumptions upon which they are based. Actual results, performance or achievements may vary materially from any projections and forward-looking statements and the assumptions on which those statements are based. Readers are cautioned not to place undue reliance on forward-looking statements and the Parties assume no obligation to update that information. This Update may contain general advice. Any general advice provided has been prepared without taking into account your objectives, financial situation or needs. Before acting on the advice, you should consider the appropriateness of the advice with regard to your objectives financial situation and needs. and consider obtaining advice from a financial advice. You should obtain a conv of the relevant PDS the advice with regard to your objectives, financial situation and needs, and consider obtaining advice from a financial advisor. You should obtain a copy of the relevant PDS or offer document before making any decisions to purchase a product. All performance figures, unit prices and distributions are in Australian Dollars, unless otherwise stated. Like all investments, an investment in any of the Funds carries risks which may result in the loss of income or principal invested. In addition to the general risks of investing, specific risks associated with investing in the Funds include, but are not limited to, private investments risk, illiquidity risk and foreign exchange risk.

For further information about the risks of investing in any of the Funds, please see the relevant Product Disclosure Statements available on the website: